News
Bioiberica participated in the Barcelona edition of BIO-Europe on 8 to 10 March 2010. It will also participate in PharmaVenue on 17-18 May in Madrid.
Bioiberica closed 2009 with a turnover of $152 million and significant growth compared to the previous year. These results indicate that the company is on the right track and heading for a promising future.
Bioiberica forms part of the consortium of companies working on the Senifood project, which carries out research on diets and foods of specific characteristics for the elderly with the aim of improving the nutrition of this age group.
Bioiberica Farma, the Spanish division of Bioiberica, has received approval for the combination of chondroitin and glucosamine in Spain. This is the first authorization of its kind in Europe.
Bioiberica is going to held during 2010 in the three most important international conferences on diseases of the musculoskeletal system: those organized by EULAR, OARSI and ACR